Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ARS PharmaceuticalsSPRY +1.51%28 EV-to-OCF is -2.84 as of Aug. 13, 2026. GuruFocus rates SPRY with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 1,407 Biotechnology companies, ARS Pharmaceuticals ranks worse than 54.02% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, ARS Pharmaceuticals's Enterprise Value is $496.34 Mil.
ARS Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-175.07 Mil. Therefore, ARS Pharmaceuticals's EV-to-OCF for today is -2.84.
The historical rank and industry rank for ARS Pharmaceuticals's EV-to-OCF or its related term are showing as below:
SPRY'
s EV-to-OCF Range Over the Past 10 Years
Min: -73.67 Med: -9.26 Max: 100.72
Current: -2.84
During the past 6 years, the highest EV-to-OCF of ARS Pharmaceuticals was 100.72. The lowest was -73.67. And the median was -9.26.
SPRY's EV-to-OCF is ranked worse than 54.02% of 1407
companies
in the Biotechnology industry
Industry Median: -3.54
vs SPRY: -2.84
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ARS Pharmaceuticals (NAS:SPRY) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ARS Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
ARS Pharmaceuticals's share price for today is $6.06.
ARS Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ARS Pharmaceuticals EV-to-OCF Related Terms
ARS Pharmaceuticals EV-to-OCF Historical Data
* Premium members only.
The historical data trend for ARS Pharmaceuticals's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ARS Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARS Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ARS Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where ARS Pharmaceuticals's EV-to-OCF falls into.
ARS Pharmaceuticals's current Enterprise Value is $496.34 Mil.
ARS Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-175.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARS Pharmaceuticals (SPRY) has a EV-to-OCF of -2.84 as of Aug. 13, 2026. According to the industry distribution chart, ARS Pharmaceuticals ranks #760 out of 1407 companies in the Biotechnology industry, placing it in the top 54%.
Is ARS Pharmaceuticals' EV-to-OCF too high?
ARS Pharmaceuticals' current EV-to-OCF is -2.84. Based on the distribution chart, ARS Pharmaceuticals ranks #760 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ARS Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does ARS Pharmaceuticals' EV-to-OCF compare to ALLO and CBIO?
According to the Biotechnology industry distribution chart, ARS Pharmaceuticals ranks #760 out of 1407 companies for EV-to-OCF. This places ARS Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. ARS Pharmaceuticals's current EV-to-OCF is -2.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARS Pharmaceuticals stock overvalued right now?
ARS Pharmaceuticals (SPRY) has a current EV-to-OCF of -2.84. The current EV-to-OCF is -2.84. ARS Pharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For ARS Pharmaceuticals (SPRY), the current EV-to-OCF is -2.84 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
28GF Score
Get the complete analysis for SPRY
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRY has been successfully added to your 
